Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Chief Legal and Admin. Officer | February 26, 2026 | March 05, 2026 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Legal Officer | November 20, 2024 | November 22, 2024 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | SVP,General Counsel & Sec. | June 01, 2017 | June 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date February 26, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.68 · Expires 2035-12-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-02-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: One-third of the shares underlying the option become vested and exercisable on January 1, 2027, and the remaining two-thirds of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 24 months following January 1, 2027, subject to the reporting person's continued service through the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: These restricted stock units ("RSUs") vest in three substantially equal annual installments at the three anniversary dates following January 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the shares underlying the option become vested and exercisable on January 1, 2027, and the remaining two-thirds of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 24 months following January 1, 2027, subject to the reporting person's continued service through the applicable vesting date.
F2: These restricted stock units ("RSUs") vest in three substantially equal annual installments at the three anniversary dates following January 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
F3: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
Immunovant, Inc.
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 319,228 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Sale · Disposed 3,650 · Balance 319,228 F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Minerva Neurosciences, Inc.
Report date June 01, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-01 · Exercise / conversion · Acquired 17,500 · Balance 17,500 Row 2 · 2017-06-01 · Sale · Disposed 17,500 · Balance 0 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2025-04-13 | Direct | 39,774 |
Reported balance
After 2017-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-01 · Exercise / conversion · Disposed 17,500 · Balance 39,774 F2: This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016.
F2: This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 133,486 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.74 · Expires 2027-06-25 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 125,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 33,333 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2030-03-01 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 15,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2031-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2024 Filed Nov 22, 2024 21:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,650 | $25.45 | $92,892.50 |
DisclosureSEC source: 0001764013-24-000196 · wk-form4_1732309949.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,228 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 20:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,361 | $29.53 | $128,780.33 |
DisclosureSEC source: 0001764013-24-000180 · wk-form4_1729887897.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,878 F1 · shares: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:28 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,860 | $28.79 | $82,339.40 |
DisclosureSEC source: 0001764013-24-000172 · wk-form4_1729283330.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,239 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 131 | $32.32 | $4,233.92 |
DisclosureSEC source: 0001764013-24-000160 · wk-form4_1724444128.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,099 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,164 | $31.84 | $100,741.76 |
DisclosureSEC source: 0001764013-24-000160 · wk-form4_1724444128.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,230 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:17 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,015 | $27.76 | $111,456.40 |
DisclosureSEC source: 0001764013-24-000141 · wk-form4_1722025015.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,394 F1 · shares: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on July 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.37 - $28.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 147 | $30.55 | $4,490.85 |
DisclosureSEC source: 0001764013-24-000137 · wk-form4_1721425350.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,409 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,358 | $29.64 | $69,891.12 |
DisclosureSEC source: 0001764013-24-000137 · wk-form4_1721425350.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,556 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,242 | $29.65 | $96,125.30 |
DisclosureSEC source: 0001764013-24-000095 · wk-form4_1716581406.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,914 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 21:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,963 | $28.90 | $114,530.70 |
DisclosureSEC source: 0001764013-24-000085 · wk-form4_1714166305.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,156 F1 · shares: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on April 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 22:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,225 | $29.94 | $66,616.50 |
DisclosureSEC source: 0001764013-24-000083 · wk-form4_1713564410.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,119 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 22:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,602 | $28.80 | $218,937.60 |
DisclosureSEC source: 0001764013-24-000083 · wk-form4_1713564410.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,344 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:37 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 68,723 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000055 · wk-form4_1712263016.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,723 Underlying: Common Stock · 68,723 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:37 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 54,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000055 · wk-form4_1712263016.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,946 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,134 | $36.15 | $77,144.10 |
DisclosureSEC source: 0001764013-24-000040 · wk-form4_1708723115.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,968 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 26, 2024 Filed Jan 29, 2024 21:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 46 | $38.45 | $1,768.70 |
DisclosureSEC source: 0001764013-24-000018 · wk-form4_1706562754.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,102 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 26, 2024 Filed Jan 29, 2024 21:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,981 | $37.91 | $113,009.71 |
DisclosureSEC source: 0001764013-24-000018 · wk-form4_1706562754.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,148 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 124 | $33.52 | $4,156.48 |
DisclosureSEC source: 0001764013-23-000137 · wk-form4_1700854876.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,129 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,128 | $32.75 | $102,442.00 |
DisclosureSEC source: 0001764013-23-000137 · wk-form4_1700854876.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,253 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,107 | $34.66 | $142,348.62 |
DisclosureSEC source: 0001764013-23-000125 · wk-form4_1698437034.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,381 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.66 - $34.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1 | $20.89 | $20.89 |
DisclosureSEC source: 0001764013-23-000105 · wf-form4_169299751230736.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,488 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 12,285 | $20.30 | $249,385.50 |
DisclosureSEC source: 0001764013-23-000105 · wf-form4_169299751230736.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,489 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.87 - $20.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,917 | $21.63 | $84,724.71 |
DisclosureSEC source: 0001764013-23-000084 · wf-form4_169048996715033.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,774 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on July 19, 2023.Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.27 - $21.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 25, 2023 Filed Apr 26, 2023 20:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,633 | $16.29 | $42,891.57 |
DisclosureSEC source: 0001764013-23-000059 · wf-form4_168253969335957.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,691 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on April 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.11 - $16.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:24 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 113,821 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000041 · wf-form4_168150383601971.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,821 Underlying: Common Stock · 113,821 shares Expires 2033-04-12 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:24 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 87,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000041 · wf-form4_168150383601971.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,324 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 12:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 10,156 | $18.51 | $187,987.56 |
DisclosureSEC source: 0001764013-23-000015 · wf-form4_167482200506238.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,660 F1 · security: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 35,750 of these RSUs vested on January 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 169,648 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000107 · wf-form4_166094266063739.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,648 Underlying: Common Stock · 169,648 shares Expires 2032-08-17 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 112,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000107 · wf-form4_166094266063739.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,816 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 22:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 383,000 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001764013-22-000027 · wf-form4_164366644858148.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,000 Underlying: Common Stock · 383,000 shares Expires 2032-01-28 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on January 19, 2023 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 22:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 143,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000027 · wf-form4_164366644858148.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on January 19, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $11.41 | Not disclosed |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · derivative · entry 6 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-02-28 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 15,500 | Not disclosed Strike: $15.78 | Not disclosed |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · derivative · entry 5 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2030-03-01 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $14.75 | Not disclosed |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · derivative · entry 4 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-02-28 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 33,333 | Not disclosed Strike: $22.31 | Not disclosed |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · derivative · entry 3 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2028-01-31 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $21.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2027-06-25 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 133,486 | $8.50 | $1,134,631.00 |
DisclosureSEC source: 0001209191-21-065712 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:45 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,945 | $6.45 | $25,445.25 |
DisclosureSEC source: 0001209191-21-047502 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,486 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on July 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $6.45. The shares were sold at a range of prices between $6.24 and $6.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001209191-21-017262 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-28 F2 · derivative.exercise_date: 25% of the shares shall vest on the one-year anniversary of January 1, 2021 (the "Vesting Commencement Date"), and thereafter 1/48th of the total shares shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four years after the Vesting Commencement Date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017262 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,431 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 17:52 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 6,829 | $11.13 | $76,006.77 |
DisclosureSEC source: 0001209191-21-002559 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,431 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on February 1, 2018, March 1, 2019, and March 2, 2020. F2 · price: The weighted average sale price for the transaction reported was $11.13. The shares were sold at a range of prices between $11.12 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043108 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,260 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:12 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,023 | $10.83 | $11,079.09 |
DisclosureSEC source: 0001209191-20-038722 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,510 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,023 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:16 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 15,500 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-20-015128 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:16 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015128 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,487 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 16:35 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002285 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,487 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on February 1, 2018 and March 1, 2019. F2 · price: The shares were sold at a range of prices between $19.74 and $19.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 938 shares of Common Stock that were acquired by the Reporting Person on December 20, 2019 at $9.89 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,213 | $9.81 | $11,899.53 |
DisclosureSEC source: 0001209191-19-038762 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,273 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,213 shares by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:29 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 18,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001209191-19-016506 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2019 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:29 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016506 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,060 Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 17:12 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 734 | $12.36 | $9,072.24 |
DisclosureSEC source: 0001209191-19-002087 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,060 F1 · shares: Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018. F2 · balance_after: Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.